@raalbany.bsky.socialGreat to be back in Chicago for the 2026 Fall Group Meeting @swog.org working alongside amazing patient advocates! #SWOGonco #oncoalert #bcam #breastcancer #breastcanceractionmonth #clinicaltrials #research #bcsm #cancer #healthequityforall #advocacy
@americancancersoc.bsky.social🚨 𝗡𝗲𝘄 𝗖𝗮𝗻𝗰𝗲𝗿 𝗦𝘁𝗮𝘁𝗶𝘀𝘁𝗶𝗰𝘀 𝗢𝘂𝘁 𝗧𝗼𝗱𝗮𝘆! 🚨
Published today in 𝘊𝘈: 𝘈 𝘊𝘢𝘯𝘤𝘦𝘳 𝘑𝘰𝘶𝘳𝘯𝘢𝘭 𝘧𝘰𝘳 𝘊𝘭𝘪𝘯𝘪𝘤𝘪𝘢𝘯𝘴, this new report from our Cancer Surveillance team reveals 𝗰𝗮𝗻𝗰𝗲𝗿 𝗶𝘀 𝘁𝗵𝗲 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗰𝗮𝘂𝘀𝗲 𝗼𝗳 𝗱𝗲𝗮𝘁𝗵 𝗶𝗻 𝘁𝗵𝗲 𝗛𝗶𝘀𝗽𝗮𝗻𝗶𝗰 𝗮𝗻𝗱 𝗟𝗮𝘁𝗶𝗻𝗼 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝗶𝗻 𝘁𝗵𝗲 𝗨𝗻𝗶𝘁𝗲𝗱 𝗦𝘁𝗮𝘁𝗲𝘀.
@protocolandpeople.bsky.socialTwo people with the same stage can have completely different grades.
Stage is how far it has spread. Grade is how the cells look under the microscope, and how fast they are likely to grow.
#clinicaltrials #trialliteracy #oncoalert
protocolandpeople.org
@ipharmaservices.bsky.socialDESTINY-Lung04：#Enhertu 在1L HER2突变 #非小细胞肺癌 击败化疗+帕博利珠单抗。
• PFS: 14.3 vs 8.3月
• ORR: 70% vs 44.5%
• OS: 29.3 vs 33.1月
@ipharmaservices.bsky.socialDESTINY-Lung04: #Enhertu supera quimio+pembro em 1L #CPNPC HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m
www.ipharmacenter.com/post/iaslc-2...
#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notícias #mídia #CâncerDePulmão
@ipharmaservices.bsky.socialDESTINY-Lung04: #Enhertu batte chemio+pembro in 1L #NSCLC HER2+ • PFS: 14,3 vs 8,3m • ORR: 70% vs 44,5% • OS: 29,3 vs 33,1m
www.ipharmacenter.com/post/iaslc-2...
#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notizie #media #TumoreAlPolmone
@ipharmaservices.bsky.socialDESTINY-Lung04: #Enhertu schlägt Chemo+Pembro in 1L HER2+ #NSCLC
• PFS: 14,3 vs 8,3M
• ORR: 70% vs 44,5%
• OS: 29,3 vs 33,1M
www.ipharmacenter.com/post/iaslc-2...
#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #Nachrichten #Medien #Lungenkrebs
@ipharmaservices.bsky.socialDESTINY-Lung04 : #Enhertu bat chimio+pembro en 1L #CBNPC HER2+
• SSP : 14,3 vs 8,3m
• TRG : 70% vs 44,5%
• SG : 29,3 vs 33,1m
www.ipharmacenter.com/post/iaslc-2...
#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CancerDuPoumon #HER2
@ipharmaservices.bsky.socialDESTINY-Lung04: #Enhertu supera quimio+pembro en 1L #CPNM HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m
www.ipharmacenter.com/post/iaslc-2...
#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CáncerDePulmón #HER2
@ipharmaservices.bsky.social@ipharmaservices.bsky.socialA $GSK adquire engajador de células T triespecífico da Chimagen por até $750M contra #MielomaMúltiplo. Fase 1 prevista para 2027: www.ipharmacenter.com/post/pharmac... #Câncer #Oncologia #Farmacêutica #OncoAlert #ASCO26
@ipharmaservices.bsky.social$GSK 斥资高达7.5亿美元收购 Chimagen 的三特异性T细胞接合器，针对 #多发性骨髓瘤，预计2027年进入一期临床：https://www.ipharmacenter.com/post/pharmaceutical-healthcare-deals-acquisitions-2026-ipharmacenter #癌症 #肿瘤学 #制药 #OncoAlert #ASCO26
@ipharmaservices.bsky.social$GSK erwirbt trispezifischen T-Zell-Engager von Chimagen für bis zu $750M gegen #MultiplesMyelom. Phase 1 für 2027 geplant: www.ipharmacenter.com/post/pharmac... #Krebs #Onkologie #Pharmazeutik #OncoAlert #ASCO26
@ipharmaservices.bsky.social$GSK acquiert un engageur de lymphocytes T trispécifique chez Chimagen pour $750M max ciblant le #MyélomeMultiple. Phase 1 en 2027: www.ipharmacenter.com/post/pharmac... #Cancer #Oncologie #Pharmaceutique #OncoAlert #ASCO26
@ipharmaservices.bsky.social$GSK adquiere un activador de células T triespecífico de Chimagen por hasta $750M contra el #MielomaMúltiple. Fase 1 prevista para 2027: www.ipharmacenter.com/post/pharmac... #Cáncer #Oncología #Farmacéutica #OncoAlert #ASCO26